Ads
related to: zydus prostate cancer
Search results
Results From The WOW.Com Content Network
In 2022, Cadila Healthcare Ltd was renamed as Zydus Lifesciences Ltd. [15] In October 2024, USFDA Approval for Prostate Cancer Drug: Zydus Lifesciences received USFDA approval to manufacture Enzalutamide tablets, which are used for treating prostate cancer. This drug, an androgen receptor inhibitor, is designed for patients with castration ...
Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. [2] [9] It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), [2] nonmetastatic castration-resistant prostate cancer, [2] and metastatic castration-sensitive prostate ...
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.
Prostate cancer is the most diagnosed cancer in men in over half of the world's countries, and the leading cause of cancer death in men in around a quarter of countries. [91] Prostate cancer is rare in those under 40 years old, [92] and most cases occur in those over 60 years, [2] with the average person diagnosed at 67. [93]
India's Zydus Lifesciences is aiming to launch its first new drug in the United States by early 2026, looking to tap into the multi-billion dollar market for treating a type of liver disease ...
For the patients with Non Small Cell Lung Cancer (NSCLC), the company introduced 'Mycidac-C' - first in the class active immunotherapy as well as drug targeting Desmocollin. [20] Some of the top brands of the company are Aciloc, Envas, Calcirol, Haem Up, Vasograin, Tricort, Fludac, Rabiloc, Trigan-D, Mycobutol and Sepsivac. [citation needed]